Johnson and Johnson: Novel Combination of Talvey and Tecvayli Suggests High Response Rates and Durable Responses in Triple-Class Refractory Patients With Relapsed or Refractory Multiple Myeloma, Including Those With Extramedullary Disease
September 28, 2024
September 28, 2024
NEW BRUNSWICK, New Jersey, Sept. 28 (TNSres) -- Johnson and Johnson issued the following news release:
* * *
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY and TECVAYLI monotherapies
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibo . . .
* * *
Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY and TECVAYLI monotherapies
* * *
RIO DE JANEIRO (September 27, 2024) - Johnson & Johnson (NYSE: JNJ) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibo . . .